
Regulus Therapeutics Inc. (NASDAQ: RGLS), relating to the proposed merger with Novartis AG. Under the terms of the agreement, Novartis will acquire Regulus for an initial payment of $7.00 per share, plus a non-tradeable CVR for $7.00 per share payable upon the achievement of a milestone in respect to regulatory approval.